WHITE PAPER: Controlled Synthesis of Lipid Nanoparticles Using the Automated Nanoparticle System


Lipid nanoparticles (LNPs) are powerful carriers for the delivery of biotherapeutics and active pharmaceutical ingredients (APIs). They are attractive due to their size and biocompatibility, which are important factors when determining the efficacy of an encapsulated API. Particle Works’ leading microfluidic technology offers a unique automated nanoparticle generation platform for the production of homogeneous, controllable, and reproducible LNPs. The ability to control LNP size from as small as 20 nm allows for a wide range of end user applications. Key features of the Automated Nanoparticle (ANP) System include running protocols with importable experiment tables to generate formulation libraries, and the ability to run in continuous mode to generate large samples once the synthesis is optimised. The ANP System’s robustness was demonstrated by comparing the data collected in ‘protocol’ library generation mode to continuous mode, where the LNP size remained consistent with a polydispersity index (PDI) of < 0.2, and values as low as 0.06 achievable after optimising the synthesis with the ANP System. By controlling the flow rate ratio (FRR), and total flow rate (TFR), facile control over LNP size is achieved. These key findings can be tailored to any formulation to expedite the development of LNP formulations for applications from gene therapy to vaccine development and drug delivery. Click her to download the white paper.